Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CV

CapsoVision Inc

Dec 12 • 04:00PM ET

12.85

-1.57 -10.89 %

Healthcare • Medical Devices • USA • NASD

Dec 11, 10:01 AMProfit-taking triggered premarket plunge after executive appointment fueled prior day's rally.

Held by: IWO IWC VTWO VXF RSSL VTWG VTWV URTY UWM ITWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	38.72%	Shs Outstand	46.80M	Perf Week	86.23%
Market Cap	601.94M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	28.73M	Perf Month	131.95%
Enterprise Value	585.13M	PEG	-	EPS next Q	-0.14	Inst Own	0.87%	Short Float	0.28%	Perf Quarter	196.77%
Income	-	P/S	-	EPS this Y	-	Inst Trans	33.41%	Short Ratio	0.61	Perf Half Y	-
Sales	-	P/B	29.42	EPS next Y	-	ROA	-	Short Interest	0.08M	Perf YTD	267.14%
Book/sh	0.44	P/C	33.84	EPS next 5Y	-	ROE	-	52W High	15.37 -16.40%	Perf Year	-
Cash/sh	0.38	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	3.43 274.19%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	34.04% 13.27%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.50	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	80.01	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.19	EPS Q/Q	-86.87%	SMA20	84.01%	Beta	-	Target Price	6.00
Payout	-	Debt/Eq	0.05	Sales Q/Q	41.80%	SMA50	125.83%	Rel Volume	2.68	Prev Close	14.42
Employees	-	LT Debt/Eq	0.03	Earnings	Nov 13 AMC	SMA200	164.66%	Avg Volume	129.54K	Price	12.85
IPO	Jul 02, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-37.10% -3.60%	Trades		Volume	346,839	Change	-10.89%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-25	Initiated	The Benchmark Company	Speculative Buy	$5
Jul-28-25	Initiated	Roth Capital	Buy	$6

Nov-20-25 04:05PM	CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference (GlobeNewswire)
Nov-13-25 04:05PM	CapsoVision Reports Third Quarter 2025 Financial Results (GlobeNewswire) -9.70%
Nov-12-25 07:28AM	CapsoVision Inc (CV) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Nov-10-25 04:05PM	CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule (GlobeNewswire) +10.22%
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Loading…
Nov-03-25 08:00AM	CapsoVision Appoints David Garcia as Senior Vice President of Finance (GlobeNewswire)
Oct-30-25 04:05PM	CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025 (GlobeNewswire)
Oct-24-25 11:15AM	Zacks Industry Outlook Highlights Exxon Mobil, Chevron and BP (Zacks)
Sep-25-25 04:05PM	CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Aug-14-25 04:05PM	CapsoVision Reports Second Quarter 2025 Financial Results (GlobeNewswire)
10:25AM	Smart Pills Company Evaluation Report 2025 \| Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies (GlobeNewswire)
Jul-31-25 04:05PM	CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025 (GlobeNewswire) -5.96%
Jul-03-25 11:50AM	CapsoVision Announces Closing of Initial Public Offering (GlobeNewswire) +25.71%
Jul-01-25 09:08PM	CapsoVision Announces Pricing of Initial Public Offering (GlobeNewswire)

CapsoVision, Inc. operates as a commercial-stage medical technology company. It engages in the development of imaging and artificial intelligence (AI) technologies that are deployed for endoscopy solutions to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. The firm developed capsule endoscope system, currently comprising the CapsoCam Plus single-use capsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease. The company was founded by Kang-Huai Wang on August 1, 2005 and is headquartered in Saratoga, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Petersen Rebecca Ann	Director of Clinical Affairs	Aug 18 '25	Option Exercise	0.37	24,834	9,097	24,834	Aug 22 08:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CV

CapsoVision Inc

Upgrade your FINVIZ experience